Report ID: SQMIG35J2106
Report ID:
SQMIG35J2106 |
Region:
Global |
Published Date: June, 2024
Pages:
219
|
Tables:
101 |
Figures:
66
September 2023: ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, has received approval from the U.S. Food and Drug Administration (FDA). This marks a huge milestone for the primary-of-its-type excessive-sustained thing VIII replacement remedy.
October 2023: Sanofi SA (SASY.PA) has received approval from the U.S. Food and Drug Administration for its remedy designed to deal with hemophilia A, a hereditary bleeding disease. The French pharmaceutical business enterprise anticipates launching the remedy inside the United States in April.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2106